rxstat › Classes › Blood Glucose Lowering Drugs, Excl. Insulins
Blood Glucose Lowering Drugs, Excl. Insulins: shortage status in Canada
10 of the 20 blood glucose lowering drugs, excl. insulins rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.
Widespread shortageCanagliflozin2 of 4 reported products affected · est. return Dec 4, 2026Widespread shortageSitagliptin12 of 24 reported products affected · est. return Jan 7, 2027Partial shortageDapagliflozin4 of 11 reported products affected · est. return Jul 24, 2026Partial shortageDapagliflozin Metformin2 of 6 reported products affected · est. return Jul 24, 2026Partial shortageGliclazide2 of 20 reported products affectedPartial shortageMetformin3 of 33 reported products affected · est. return May 15, 2026Partial shortagePioglitazone5 of 36 reported products affectedPartial shortageRepaglinide6 of 21 reported products affected · est. return Sep 4, 2026Partial shortageSaxagliptin1 of 4 reported products affected · est. return Jul 10, 2026Partial shortageSitagliptin Metformin7 of 23 reported products affected · est. return Jul 20, 2026Shortage anticipatedGlyburide0 of 10 reported products affectedDiscontinuedAcarbose0 of 2 reported products affectedDiscontinuedChlorpropamide0 of 2 reported products affectedNo current shortageDulaglutideDiscontinuedExenatide0 of 3 reported products affectedDiscontinuedLinagliptin Empagliflozin0 of 2 reported products affectedNo current shortageLiraglutideDiscontinuedMetformin Rosiglitazone0 of 4 reported products affectedDiscontinuedMetformin Saxagliptin0 of 3 reported products affectedDiscontinuedTolbutamide0 of 1 reported products affected
Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.